ClinicalTrials.gg
RecruitingNCT07903415Updated Nov 16, 2026

A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.

A Phase 1 interventional study of PF-08098488 in Pancreatic Ductal Adenocarcinoma, Esophageal Cancer and Carcinoma, Non-Small-Cell Lung (NSCLC), sponsored by Pfizer. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Updated Nov 16, 2026Start date movedEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
280
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Esophageal Neoplasms by Pfizer — 4 open to participants now, 5 under way, none of them phase 3. Esophageal Neoplasms · Pfizer.

Planned enrollment
3rd of 12
280 · median 100
Started
2026
with 1 other
Phase 1
8 of 12
4 open now
Registered
12th of 12
by date

Among the 12 studies in Esophageal Neoplasms by Pfizer, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2026, is one of 8 in phase 1, and was the 12th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 503 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

4 of the 12 studies in Esophageal Neoplasms by Pfizer are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 388 Esophageal Neoplasms studies recruiting now, 246 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Esophageal Neoplasms by Pfizer, or all of them as a file.
02

Study summary

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called PF-08098488) in people with advanced solid tumors (cancer that cannot be removed with surgery or has spread to other parts of the body). PF-08098488 is being studied as a possible treatment for certain types of cancer. These include non-small cell lung cancer, pancreatic cancer, stomach or gastroesophageal junction cancer, and esophageal cancer. This study will also help researchers learn how the study medicine moves through and affects the body.

This study is seeking adults who:

  • Have advanced non-small cell lung cancer, pancreatic cancer, stomach or gastroesophageal junction cancer, or esophageal cancer.
  • Have received at least 1 previous treatment for their cancer.
  • Have cancer that has grown, returned, or is no longer responding to available treatments.

All participants in this study will receive PF-08098488 as an IV infusion (given directly into a vein) at the study clinic. Researchers will study different dose levels and dosing schedules to find the dose that is safe and may work best. Participants will be monitored closely during treatment, especially after their first infusion. They may continue receiving the study medicine as long as their cancer is not getting worse and they are tolerating treatment.

The study includes a screening period of up to 28 days. Participants will have regular visits to the study clinic for treatment and health assessments. These assessments include scans to monitor the cancer and blood sample collection. Tumor tissue samples will also be collected when available or medically feasible. After treatment ends, participants will have a follow-up visit about 1 month later. They will then be contacted about every 12 weeks to check on their health.

03

Conditions studied

  • Pancreatic Ductal Adenocarcinoma
  • Esophageal Cancer
  • Carcinoma, Non-Small-Cell Lung (NSCLC)
  • Gastric Carcinoma
  • Gastroesophageal Junction Adenocarcinoma

Keywords

  • NSCLC
  • Pancreatic Cancer
  • Stomach Cancer
  • Gastric Cancer
  • Esophageal Cancer
  • metastatic cancer
  • advanced cancer
  • solid tumors
  • Lung Cancer
04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • Advanced non-small cell lung cancer, pancreatic ductal adenocarcinoma, gastric cancer (including gastroesophageal junction carcinoma), or esophageal cancer.
  • Performance status 0-1
  • Must have received at least 1 prior approved systemic therapy:
  • Part 1: progression or relapse following standard treatments and have no other appropriate standard of care option.
  • Part 2: maximum of 2 in the advanced setting.
  • Resolution of acute effects of prior anticancer therapy to baseline or Grade 1
  • Consent to submit required pre-treatment tumor tissue as medically feasible

Exclusion criteria

Exclusion Criteria:

  • Received prior treatment with an antibody drug conjugate with an auristatin or microtubule inhibitor payload.
  • Unacceptable renal, hepatic, hematologic, cardiologic, pulmonary, or abnormalities as defined by the protocol.
  • Pre-existing sensory or motor neuropathy.
  • Uncontrolled diabetes mellitus.
  • and/ or symptomatic eye disease meeting protocol exclusion criteria.
  • Pulmonary (lung) disease meeting protocol exclusion criteria.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    Part 1 Dose Escalation

    Different groups of participants will receive different doses and/or schedules of the study drug

    Drug: PF-08098488

  • Experimental
    Part 2 Dose Expansion

    Participants in tumor-specific groups will receive 1 dosing regimen deemed to be safe in Part 1

    Drug: PF-08098488

  • Experimental
    Part 2 Dose Optimization

    Participants will be assigned to one of two dosing regimens deemed to be safe in Part 1

    Drug: PF-08098488

Interventions

  • DrugPF-08098488

    IV infusion

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs)

    Number of participants with AEs, characterized by type, frequency, severity, seriousness, and relationship to study intervention during the AE evaluation period.

    Time frame: Start of study treatment to 30 days after the last dose of study drug administration or start of new anticancer therapy (whichever occurs first)

  2. Part 1: Recommended Monotherapy Dose(s) for Expansion (RDEM)

    Time frame: From first dose through completion of Part 1, an average of 1 year

  3. Part 2: Recommended Monotherapy Dose for Further Development

    Time frame: From first dose through completion of Part 2, an average of 2 years

Secondary outcomes

  1. Objective Response Rate (ORR)

    Percentage of participants with a confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the investigator.

    Time frame: From baseline until first documented disease progression, death, or start of new anticancer therapy, whichever occurs first, up to approximately 3 years

  2. Duration of Response (DOR)

    Time in weeks/months from the first documentation of objective tumor response to objective tumor progression or death due to any cancer.

    Time frame: From the date of first objective response until disease progression or death due to any cause, whichever occurs first, up to approximately 3 years

  3. Progression Free Survival (PFS)

    PFS as defined per RECIST 1.1.

    Time frame: From first dose until disease progression or death due to any cause, whichever occurs first, up to approximately 3 years

  4. Overall Survival (OS)

    Time in weeks from the start of study treatment to date of death due to any cause.

    Time frame: From first dose until death due to any cause, up to approximately 3 years

  5. Maximum Observed Serum Concentration (Cmax)

    Time frame: From first dose through End of Treatment (EOT), up to approximately 3 years

  6. Area under the concentration-time curve (AUC)

    Time frame: From first dose through End of Treatment (EOT), up to approximately 3 years

  7. Time to Maximum Observed Serum Concentration (Tmax)

    Time frame: From first dose through End of Treatment (EOT), up to approximately 3 years

  8. Number of Participants With Anti-drug Antibody (ADA) against PF-08098488

    Time frame: Start of study treatment to 30 days after last dose of study drug administration

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Jan 2031, 50 months after the start.

Of 78 industry-sponsored phase 1 interventional studies under Esophageal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 70. This study's planned 50 months is close to that.

Counting every sponsor, half of 126 studies reached it within 48 months; a quarter within 29 and three quarters within 76.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2026
First posted
Oct 29, 2026
StartActual
Nov 5, 2026was Oct 2026
Primary completionEst.
Jan 26, 2031
CompletionEst.
Jan 26, 2032
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 United States)
  • Sarah Cannon Research Institute - Pharmacy · Nashville, United States
  • SCRI Oncology Partners · Nashville, United States
Nov 3, 2026
Start date
Oct 29, 2026→Nov 5, 2026 (actual)
Nov 16, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedEastern Cooperative Oncology Group (ECOG) Performance status 0-1
Nov 16, 2026
Registered
First appeared on the registry
Oct 29, 2026
Show all 3 updates
  1. Nov 16, 2026
    Start date Oct 29, 2026→Nov 5, 2026 (now actual)
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedEastern Cooperative Oncology Group (ECOG) Performance status 0-1
  2. Nov 3, 2026
    2 sites added
    Show 2 added (2 United States)
    • Sarah Cannon Research Institute - Pharmacy · Nashville, United States
    • SCRI Oncology Partners · Nashville, United States
    + 1 other change: verification date
  3. Oct 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07903415
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 29, 2026
Start date
Nov 5, 2026
Primary completion
Jan 26, 2031 (estimated)
Completion
Jan 26, 2032 (estimated)
Last update
Nov 16, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion